Hybrigenics

EG: ALHYG

€9.8m market cap

€0.21 last close

Hybrigenics is a French biotech company. It is developing its lead drug, inecalcitol, against orphan adult leukaemias and is currently conducting an international Phase II study in acute myeloid leukaemia. The company has a research programme on USP inhibitors and an R&D collaboration with Servier focused on USP inhibitors in oncology.

Investment summary

Edison Investment Research is terminating coverage on Hybrigenics (ALHYG). Please note you should no longer rely on any previous research or estimates for this company. All forecasts should now be considered redundant.

Y/E Dec
Revenue (€m)
EBITDA (€m)
PBT (€m)
EPS (c)
P/E (x)
P/CF (x)
2016A 2.6 (3.5) (4.0) (11.2) N/A N/A
2017A 1.9 (6.8) (7.3) (17.7) N/A N/A
2018E 3.6 (3.5) (4.1) (8.7) N/A N/A
2019E 2.2 (3.3) (4.0) (7.6) N/A N/A
Sector
Healthcare
Share price graph
Balance sheet
Forecast net cash (€m) 1.5
Forecast gearing ratio (%) N/A
Price performance
%
1m
3m
12m
Actual 122.1 (49.1) (66.9)
Relative* 125.9 (45.3) (61.6)
52-week high/low €0.7/€0.0
*% relative to local index
Key management
Alain Muňoz Chairman
Rémi Delansorne CEO
Guillaume Floch CFO
Company website

Content on Hybrigenics

Show all

Hybrigenics – Termination of coverage

Healthcare research
Termination
4 January 2019

Hybrigenics – Leukaemia pipeline advances with new data

Healthcare research
Update (1-4pgs)
24 May 2018

Hybrigenics – Inecalcitol advancing towards data

Healthcare research
Outlook
31 January 2018

Hybrigenics – H117 results released, business on track

Healthcare research
Non-client QV
15 November 2017

You may also be interested in…

Cookies

This site uses cookies: Find out more.